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Objective: Reports on the epidemiology of vestibular schwannoma (VS) indicate an
increase in diagnosed cases, often based on selected materials over a limited period of
time. This report presents prospective 40-year epidemiological data from an unselected
national cohort of all patients diagnosed with a VS in Denmark since 1976.
Study-design: Data on gender, age, tumor localization and size registered during the period
1976–2015 were retrieved.
Results: 3637 new cases of VS were diagnosed during the 40-year period. The annual
number of diagnosed VS increased from 14 in 1976 to 193 in 2015. Mean extrameatal tumor
size decreased from 26mm in 1976 to 13.4mm in 2015. Large and giant tumors were more
frequent during the first decades, whereas predominantly smaller tumors were diagnosed
during the recent years. Median age at diagnosis increased gradually from 49.2 years in 1976
to 60 years in 2015.
Conclusion: Over the past 40 years, the incidence rate of vestibular schwannomas has
increased steadily from 3 VS/million/year to 34 VS/million/year, primarily due to easier
access to improved diagnostics and the finding of more tumors in older people. Concurrently,
the diagnostic tumor size has decreased from 26mm to 7mm, and the age at diagnosis has
increased from 49 to 60 years.
Keywords: acoustic neuroma, age, incidence, tumor localization, tumor size
Introduction
All vestibular schwannomas diagnosed in Denmark have been managed at our tertiary
referral center and registered prospectively in a database since 1976. Prior to this, data
occur primarily in Danish neurosurgical publications.1 Following the initiation of the
database and the introduction of the translabyrinthine approach,2 the recorded inci-
dence rate of VS has been published successively, firstly by Tos and Thomsen andmore
lately by Stangerup et al.1,3–7 In 2004, an increasing incidence rate of VS was reported,
based on 1446 patients diagnosed during the period from 1976 to 20011 and in 2010
reported further increasing to a peak of 22.8 VS/million in 2004.6 In 1976, the annual
incidence rate was 3.1 VS/million, increasing to 19.4 VS/million in 2008, based on
2283 patients.6
Several other studies have also published data showing an increasing incidence rate
of VS. Generally, incidences between 10 and 20 VS/million/year are reported, includ-
ing data from America (Nestor et al8), Canada (Frohlich and Sutherland9), United
Kingdom (Evans et al10) and locally in Denmark (Mirz et al11). Lately, American
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population-based registry studies have found similar inci-
dences. Thus, Carlson et al12 reported an incidence rate of
11 VS/million/year based on 8330 patients diagnosed during
the period 2004–2011, and data on 23,729 patients registered
in the Central Brain Tumor Registry of the United States
during the period 2004–2010 showed an incidence rate of
10.9 million/year.13 An earlier publication from the same
registry reported an incidence rate of 6 VS/million/year.14
From the Netherlands Cancer Registry, a publication from
2016 reported on 3663 patients diagnosed with VS during the
period 2001 to 2012, showing an increase in incidence rate
from 10.3 to 15.5 VS/million/year.15 From Taiwan, a pub-
lication reported an increase in incidence rate from
26.6/million in 2001 to 37.2/million in 2012.16 Lastly, in
2018, a publication from the USA (Minnesota) reported an
increase in incidence rate from 15 VS/million/year in 1966 to
42 VS/million/year in 2016.17
The aim of this study is to report prospective 40-year
epidemiological data from the Danish VS database, which
contains the unselected, unbiased national cohort of all
Danish patients diagnosed with a VS since 1976. Data on
incidence rate, gender, age at diagnosis, tumor localization
(purely intrameatal or extrameatal) and size registered
during the period 1976–2015 are presented.
Methods
Since 1976, data from all patients in Denmark with a spora-
dic/unilateral VS have been referred to our national treatment
center, at which the patient data have been entered prospec-
tively into the national VS database. The data are thus unse-
lected and unbiased. Among other data, the tumor size, the
tumor localization, the initial treatment strategy, gender and
age of the patient at diagnosis were registered. The tumors
were categorized as either intrameatal or extrameatal (intra-
and extrameatal). The size of the extrameatal tumors was
determined as the largest extrameatal diameter by linear
measurements. This classification follows the Tokyo recom-
mendations on reporting size of VS.18
This study reports the data on the annual incidence
rate, the tumor localization and size at diagnosis, the age
at diagnosis, and the relation between age and tumor size
at diagnosis during the 40-year period from January 1,
1976 to January 1, 2016. A total of 3637 patients with
sporadic/unilateral VS were registered and included in the
database during this period, thus excluding patients diag-
nosed with Neurofibromatosis 2. The population in
Denmark was 5.1 (5.065) million in 1976, increasing to
5.7 (5.707) million as of January 1, 2016.
Results
Gender And Tumor Localization At
Diagnosis
Of the 3637 diagnosed patients, 1804 were female and 1833
male. 1095 of the tumors had an intrameatal localization at
diagnosis and 2509 were extrameatal. Localization data is
missing for 33 patients (Table 1).
Annual Incidence Rate
Since 1976, the annual number of diagnosed VS has
increased almost linearly from 14 tumors in 1976 to 193 in
2015 (Figure 1), corresponding to an increase in incidence
rate from 2.8 VS/million/year in 1976 to 33.8 VS/million/
year in 2015.
Diagnostic Tumor Size
Diagnostic tumor size has decreased markedly, from a
mean size of 27.6 mm in the period 1976 to 1978 to
7 mm in 2015 for all tumors (Figure 2). The mean extra-
meatal tumor size was 26 mm in 1976 decreasing to
13.4 mm in 2015. During the first three years, no intra-
meatal tumors were found, whereas such tumors consti-
tuted nearly half of the diagnosed tumors at the end of the
40-year period (Figure 3). The large and giant tumors
constituted 40% of all tumors during the first years, only
a few percent toward the end of the period (Figure 3).
Table 1 Patients diagnosed with a VS in Denmark during the 40-
year period 1976–2015
Patients Tumor Localization Total
No Data Intrameatal Extrameatal
Female 18 499 1287 1804
Male 15 596 1222 1833
Total 33 1095 2509 3637
Figure 1 Annual number of diagnosed vestibular schwannomas in Denmark during
the 40-year period 1976–2015. The Danish population was 5.1 million in 1976 and
5.7 million in 2015.
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Patient Age At Diagnosis
The median age at diagnosis has increased slowly, from
49.2 years in 1976 to 60 years in 2015 (Figure 4). The age
distribution at the time of diagnosis changed during the
period, as seen in Figure 5. Initially, 51% of the VS patients
were 50 years or younger, decreasing to 18% at the end of
the period (Figure 5). In contrast, only 2.8% of the patients
were older than 70 years in the beginning of the period,
increasing to 26% at the end of the period.
Tumor Size And Age At Diagnosis
Table 2 shows that the tumor size at diagnosis was larger
in younger patients and smaller in older patients. Thus,
patients below the age of 40 years had a mean tumor size
of 19.7mm extrameatal, whereas patients above the age of
60 years had a mean tumor size of 11.1mm extrameatal.
Discussion
This prospective study on 40-year epidemiological data from
the unselected, unbiased national cohort of all Danish
patients diagnosed with a VS since 1976 shows that the
incidence rate of diagnosed tumors has been increasing stea-
dily over the years, from 2.8 VS/million/year in 1976 to 33.8
VS/million/year in 2015. Improved diagnostics and
increased availability of improved diagnostics are probably
the main reasons for this increase, although an increased
tumor occurrence cannot entirely be ruled out. The first
MRI scanner in Denmark was functional in 1989 and by
2015, the number had increased to approximately 100.
Increased awareness among patients and physicians is likely
a contributing factor, as is an increasing number of older
people, who in addition may be less and less likely to accept
even a small loss of hearing, thus seeking a physician. More
and more incidental findings due to an increased number of
MRI scans, performed for reasons other than hearing loss, is
also likely to be part of the explanation. On this basis, it is
reasonable to assume that the incidence rate will increase
continuously over the coming years.
Studies with higher incidence rates, ie 37,16 4217 or
5419 VS/million/year, have been published, from eg USA.
Figure 2 Mean tumor size at diagnosis over the 40-year period 1976–2015.
Figure 3 Proportions of different tumor size groups (in mm) over the 40-year
period 1976–2015.
Figure 4 Median patient age at diagnosis over the 40-year period 1976–2015.
Figure 5 Proportions of different age groups over the 40-year period 1976–2015.
Table 2 Mean tumor size (mm extrameatal ±SD) related to age
at diagnosis in patients diagnosed with a VS during the 40-year
period 1976 – 2015
Age groups Female Male All
≤40 20.8 ±16.8 18.7 ±16.5 19.7 ±16.6
40–60 14.6 ±13.6 13.1 ±13.5 13.8 ±13.6
>60 12.0 ±12.7 10.0 ±11.5 11.1 ±12.2
All 14.2 ±13.9 12.5 ±13.4 13.3 ±13.7
Dovepress Reznitsky et al
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A number of biases may be contributing, including easier
access to health care in more affluent parts of the world or
less strict criteria of indication to perform MRI, based on
eg tinnitus, a smaller degree of hearing loss, or any other
symptom or finding that may lead to MRI of the head and
thus an incidental tumor finding. The two reports from
America both have populations with easier access to the
healthcare system (ie Mayo Clinic, Rochester) or belong to
a very affluent part of the population (ie Beverly Hills,
California). Denmark has a state-funded healthcare system
financed through general taxation and every citizen can
consult an ENT specialist (and have an MRI if indicated)
free of charge and without a referral. Despite this, even in
a very equal and homogeneous population such as the
Danish, a study on socio-demographic factors demon-
strated lower incidence rates in remote parts of the country
which is relatively small, but the same diagnostic age and
tumor size across the country.20 Thus, socio-economic and
socio-demographic factors can explain some of the differ-
ences in reported incidence rates but are unlikely to
directly explain the degree of occurrence of higher inci-
dences reported by other centers.
Over the four decades, diagnostic tumor size has
decreased steadily, from 28 mm extrameatal in the late
seventies to 7 mm extrameatal in 2015, which is in agree-
ment with an increased incidence rate associated with
improved diagnostic tools (contemporary imaging can
detect very small tumors, which were undetectable before
the introduction of MRI). It is also in agreement with the
assumption that patients seek medical consultation based
on fewer symptoms. Thus, tumors are found at an earlier
stage of development, when the tumor size is smaller.
Tumor aggressiveness appears to be inversely related
to age, as in general, large tumors are found in young
patients, small tumors in older patients. This is corrobo-
rated, but remain unexplained, by studies on the natural
history of tumor growth, as small intrameatal tumors
(usually found in older patients) are less likely to grow
compared to larger, extrameatal tumors (which are usually
found in younger patients).7 Studies on tumor gene expres-
sion have demonstrated the association between growth
and expression of certain genes and activation of specific
molecular pathways but have not accounted for age-related
tumor aggressiveness.21
Age at tumor diagnosis is steadily increasing, from
49.2 years of age to currently 60 years of age. Demography
in Denmark, and in general, is shifting progressively towards
older people, which may also be a major reason for the
increasing age at diagnosis. In addition, older people are
more likely to seek a physician and have an MRI performed
due to higher morbidity in general, but certainly also due to the
occurrence of age-related hearing loss. Finally, in continuation
of the discussion on improved diagnostics, the small tumors
within the older patient group were simply not found pre-
viously, before the introduction of MRI.
The etiopathogenesis of sporadic/unilateral VS is unac-
counted for and several studies have investigated risk fac-
tors and associations with VS. No obvious risk factors have
been found regarding age and gender. Viral infection has
been indicated,21–23 which is in line with the fact that these
tumors have been occurring for centuries. In continuation of
this, the theory of inflammation as a cause of VS has given
rise to studies and reported association to chickenpox,24 hay
fever25 and conflicting studies of the protective effects of
aspirin/NSAID.26–29 Furthermore, a few studies have
reported tobacco use (not snuff tobacco) being inversely
related to VS occurrence, although this is poorly
understood.25,30–33 None of the studies are prospective,
randomized or blinded but mostly case–control studies. Of
importance, no association has been found between occu-
pation, traffic/loud noise nor the use of mobile phones and
tumor occurrence.34–37 Lastly, exposure to radiation is
known to cause neoplasms including intracranial.38–41
Conclusion
Over the past 40 years, the incidence rate of vestibular
schwannomas has increased steadily from approximately
3 VS/million/year to 34 VS/million/year, primarily due to
continuously easier access to improved diagnostics and the
finding of more tumors in older people. Concurrently, the
diagnostic tumor size has decreased from 26 mm to 7 mm,
and the age at diagnosis has increased from approximately
49 to 60 years of age.
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